<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01433887</url>
  </required_header>
  <id_info>
    <org_study_id>TAH5010G6HCV</org_study_id>
    <nct_id>NCT01433887</nct_id>
  </id_info>
  <brief_title>Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6</brief_title>
  <official_title>Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Chinese patients with chronic hepatitis C have a different genetic background, which had
      been demonstrated to significantly influence their responses to pegylated interferon and
      ribavirin. In this study, Chinese patients with Hepatitis C Virus genotype 1, 2/3, 6
      infection were treated with pegylated interferon and ribavirin. Their response was compared
      amongst different genotypes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virological response (SVR)</measure>
    <time_frame>24 weeks after the end of treatment</time_frame>
    <description>Undetectable HCVRNA in serum(&lt;15IU/ml) 24 weeks after the end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in health related quality as measured by short form 36 (SF-36) from baseline to 24 weeks after the end of treatment</measure>
    <time_frame>24 weeks after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sick leave in patients treated for 24 or 48 weeks treatment</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">535</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Genotype 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genotype 6 chronic hepatitis C patients will be treated with Peginterferon alfa-2a plus ribavirin for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genotype 1 chronic hepatitis C patients will be treated with Peginterferon alfa-2a plus ribavirin for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 2/3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genotype 2/3 chronic hepatitis C patients will be treated with Peginterferon alfa-2a/2b plus ribavirin for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>48-weeks course</intervention_name>
    <description>patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks</description>
    <arm_group_label>Genotype 6</arm_group_label>
    <arm_group_label>Genotype 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks</description>
    <arm_group_label>Genotype 6</arm_group_label>
    <arm_group_label>Genotype 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa2a</intervention_name>
    <description>patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks</description>
    <arm_group_label>Genotype 2/3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks</description>
    <arm_group_label>Genotype 2/3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCV RNA is positive

          -  Treatment naive

          -  Come from China

        Exclusion Criteria:

          -  Active substance abuse

          -  Poorly controlled psychiatric disease

          -  HBsAg positive

          -  Anti-HIV positive

          -  Suffering from other significant concurrent medical conditions including chronic liver
             diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Eighth People's Hospital of Guangzhou</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Affliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan second people's hospital</name>
      <address>
        <city>Zhongshan</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2011</study_first_submitted>
  <study_first_submitted_qc>September 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2011</study_first_posted>
  <last_update_submitted>November 14, 2014</last_update_submitted>
  <last_update_submitted_qc>November 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Cai Qingxian</investigator_full_name>
    <investigator_title>Sun Yat-Sen University</investigator_title>
  </responsible_party>
  <keyword>Peginterferon alfa-2a</keyword>
  <keyword>ribavirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

